Charite Universitaetsmedizin Berlin KöR
Charite Universitaetsmedizin Berlin KöR is recorded as a service provider in 24 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 24 trials · Latest update first
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale® Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B
Sponsor Opella Healthcare Group S.A.S.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)
Sponsor Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
B-cell depletion for the treatment of patients with amyotrophic lateral sclerosis (ALS) - A Randomized, Double-blind, Placebo controlled Pilot Study in Patients with Amyotrophic Lateral Sclerosis for the Evaluation of Efficacy and Safety of B-Cell Depletion with Rituximab (ABCD)
Sponsor Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Imlifidase in ANCA-associated Vasculitis
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
Sponsor University Of Cologne
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Sympomatic Despite Treatment with H1 Antihistamines and/or Omalizumab, or who Cannot Tolerate Omalizumab
Sponsor Jasper Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Mono-Center, Prospective Biomarker Study to investigate the differences in the inflammatory gene expression signature, the distribution of immune cells, psoriasis-driving factors and signaling molecules between classic and hard-to-treat psoriasis plaques and the effects of TYK2 blockade with deucravacitinib – MED-PSO
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to placebo tablets participants with post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of ME/CFS criteria - VERI-LONG
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Sponsor Cellerys AG
- Start (EU)
- Latest update
- Estimated end
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer - FIRE-8 - AIO-KRK/YMO-0519
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
Sponsor Escient Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study - ClonDoTrial
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Charite Universitaetsmedizin Berlin KöR?
The 2026-10-09 snapshot links Charite Universitaetsmedizin Berlin KöR to 24 distinct CTIS trials. Recorded services include Clinical monitoring, Laboratory services, Data management, Regulatory services, among 20 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Charite Universitaetsmedizin Berlin KöR?
The most frequently recorded therapeutic areas are Gastroenterology, Neurology, Solid Tumor Oncology, Gynecology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Charite Universitaetsmedizin Berlin KöR conducted?
The linked trials record locations in 14 countries, including Germany, Czechia, Italy, Poland, Austria. These are trial locations, not confirmed office locations or countries where Charite Universitaetsmedizin Berlin KöR delivered services.
What can this page tell me about Charite Universitaetsmedizin Berlin KöR's trial experience?
Browse 24 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Charite Universitaetsmedizin Berlin KöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Charite Universitaetsmedizin Berlin KöR